The impact and risk factors for developing pneumogenic bacteremia in carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in the intensive care unit: A multicenter retrospective study

Int J Infect Dis. 2024 Sep:146:107128. doi: 10.1016/j.ijid.2024.107128. Epub 2024 Jun 8.

Abstract

Objectives: This study analyzed the risk and impact of developing pneumogenic bacteremia in patients with CRAB nosocomial pneumonia in ICU.

Methods: This is multicenter retrospective study. Clinical outcomes were compared between bacteremia and non-bacteremia group, and the risk factors for mortality and developing pneumogenic CRAB bacteremia were analyzed.

Results: After patient recruitment, 164 cases were in the bacteremia group, and 519 cases were in the non-bacteremia group. The bacteremia group had 22.4 percentage of increase in-hospital mortality than the non-bacteremia group (68.3% vs 45.9%, P < 0.001). Multivariate analysis showed bacteremia was an independent risk factor for in-hospital mortality (aHR = 2.399, P < 0.001). A long time-interval between ICU admission and pneumonia onset was an independent risk factor for developing bacteremia (aOR = 1.040, P = < 0.001). Spearman's rank correlation analysis indicated a high correlation between the days from ICU admission to pneumonia onset and the days of ventilator use before pneumonia onset (correlation coefficient (ρ) = 0.777).

Conclusions: In patients with CRAB nosocomial pneumonia, bacteremia increased the in-hospital mortality, and a longer interval from ICU admission to pneumonia onset was an independent risk factor for developing bacteremia, which was highly associated with the use of mechanical ventilation.

Keywords: Bacteremia; Carbapenem-resistant Acinetobacter baumannii; Mortality; Nosocomial pneumonia; Risk factor.

Publication types

  • Multicenter Study

MeSH terms

  • Acinetobacter Infections* / drug therapy
  • Acinetobacter Infections* / epidemiology
  • Acinetobacter Infections* / microbiology
  • Acinetobacter Infections* / mortality
  • Acinetobacter baumannii* / drug effects
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / epidemiology
  • Bacteremia* / microbiology
  • Bacteremia* / mortality
  • Carbapenems* / pharmacology
  • Carbapenems* / therapeutic use
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Female
  • Healthcare-Associated Pneumonia / epidemiology
  • Healthcare-Associated Pneumonia / microbiology
  • Healthcare-Associated Pneumonia / mortality
  • Hospital Mortality*
  • Humans
  • Intensive Care Units*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors

Substances

  • Carbapenems
  • Anti-Bacterial Agents